Evaluation the Potential of Novel Antitumor Candidates on Ehrlich Ascites Tumor-Bearing Mice

In our previous work fused pyrimidine and thiopyrimidine nucleoside analogs (2, 3b, 3c, 4a and 4c) as well as sulfated oligosaccharides (Maltose SO4, Raffinose SO4, Stachyose SO4, Chondroitin-6-sulfate, Maltohexaose SO4) were prepared. The objective of this study was to elucidate the antitumor activity of prepared compounds against Erlich ascites carcinoma cells (EAC) bearing mice through monitoring the tumor volume and life span of the mice using ascites tumor and solid tumor models. The results revealed that all the tested compounds when supplemented at 1/10 of their LD50 (median lethal dose), showing antitumor potential and caused increased in the life span of mice. Otherwise, the antitumor potential in simultaneous treatment groups was higher than the groups in which treatment was started 10 day post tumor inoculation. Compound 3C and Maltose SO4 showed highest activity on reduction tumor volume from 5.30±0.60 CC in control mice to 2.20±0.19 and 2.00±0.18 CC respectively, while the positive drug, doxorubicin treated group revealed reduction of tumor volume from 5.30±0.60 to 1.10±0.14 CC. Otherwise 3C and Maltose SO4 also showed the most highest survival rate (39.00±2.70 and 40.00±3.40 days, respectively) with the increase of life span 77% and 82% respectively compared to control, while doxorubicin showed increased in survival rate by 86% (41.00±4.30 days) as compared to control. It is obviously from the present study that the tested compounds especially 3c and Maltose SO4 possessed antitumor activity and prolong the life span of mice bearing tumor.